Trial reportBritish journal of haematology2012
Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).
Trial report in British journal of haematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00951808 (Preventing Acute Chest Syndrome by Transfusion Feasibility Study), which is not on this map. Cited by 24 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Preventing Acute Chest Syndrome by Transfusion Feasibility Study( PROACTIVE Feasibility Study)
Who cites it
24 citing papers in PubMed, 5 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Blood transfusions for treating acute chest syndrome in people with sickle cell disease.The Cochrane database of systematic reviews · 2020Pooled it
- Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease.The Cochrane database of systematic reviews · 2019Pooled it
- Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.The Cochrane database of systematic reviews · 2018Pooled it
- Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease.The Cochrane database of systematic reviews · 2016Pooled it
- Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov.Clinical trials (London, England) · 2015Pooled it
- SWIM (sickle with ibuprofen and morphine) randomised controlled trial fails to recruit: lessons learnt.BMJ open · 2016Trial
- A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children.Blood · 2015Trial
- Trial
- Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea.Pediatric blood & cancer · 2013Trial
- Trial
- Biomarkers for the diagnosis and phenotyping of acute chest syndrome in patients with sickle cell disease.Expert review of respiratory medicine · 2026Review
- Acute Chest Syndrome in Children with Sickle Cell Disease: A Narrative Review.Children (Basel, Switzerland) · 2026Review
- Emergency care for children with sickle cell disease: a focus on pain and fever.Expert review of hematology · 2025Review
- Trends, Predictors, and Outcomes of Critically Ill Patients With Sickle Cell Disease in the United States.EJHaem · 2025Article
- Lipid and hemolysis parameters predicting acute chest syndrome in adulthood with sickle cell disease.Lipids in health and disease · 2024Article
- Baseline and Disease-Induced Transcriptional Profiles in Children with Sickle Cell Disease.Scientific reports · 2020Article
- Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report.Annals of the American Thoracic Society · 2019Article
- Therapeutic strategies for sickle cell disease: towards a multi-agent approach.Nature reviews. Drug discovery · 2019Review
- Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.Hematology. American Society of Hematology. Education Program · 2018Review
- State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.Paediatric drugs · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 1 country.
Funding
Abstract
Acute chest syndrome (ACS) is defined as fever, respiratory symptoms and a new pulmonary infiltrate in an individual with sickle cell disease (SCD). Nearly half of ACS episodes occur in SCD patients already hospitalized, potentially permitting pre-emptive therapy in high-risk patients. Simple transfusion of red blood cells may abort ACS if given to patients hospitalized for pain who develop fever and elevated levels of secretory phospholipase A2 (sPLA2). In a feasibility study (PROACTIVE; ClinicalTrials.gov NCT00951808), patients hospitalized for pain who developed fever and elevated sPLA2 were eligible for randomization to transfusion or observation; all others were enrolled in an observational arm. Of 237 enrolled, only 10 were randomized; one of the four to receive transfusion had delayed treatment. Of 233 subjects receiving standard care, 22 developed ACS. A threshold level of sPLA2 ≥ 48 ng/ml gave optimal sensitivity (73%), specificity (71%) and accuracy (71%), but a positive predictive value of only 24%. The predictive value of sPLA2 was improved in adults and patients with chest or back pain, lower haemoglobin concentration and higher white blood cell counts, and in those receiving less than two-thirds maintenance fluids. The hurdles identified in PROACTIVE should facilitate design of a larger, definitive, phase 3 randomized controlled trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.